Targeting HDAC1, HDAC2 or pan-HDACs with various HDAC inhibitor classes of short-chain fatty acids, cyclic benzamides, hydroxamate derivates and Diallyl-trisulfides (DATS) might be a rational for targeting ALT in gliomas (reviewed in [159]). Here, HDAC9 is linked to glioma.